Retrospective analysis of sorafenib as first- or second-line targeted therapy in patients with mRCC: Three-year Italian experience.
Giuseppe Procopio
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Pfizer
Honoraria - AVEO; Bayer; GlaxoSmithKline; Pfizer
Alfredo Falcone
No relevant relationships to disclose
Lisa Derosa
No relevant relationships to disclose
Angela Gernone
No relevant relationships to disclose
Evaristo Maiello
No relevant relationships to disclose
Franco Morelli
No relevant relationships to disclose
Teodoro Sava
No relevant relationships to disclose
Vittorina Zagonel
Honoraria - Cephalon; GrĂ¼nenthal Group; Pfizer; Roche
Ugo De Giorgi
No relevant relationships to disclose
Vittorio D. Ferrari
No relevant relationships to disclose
Roberto Sabbatini
No relevant relationships to disclose
Cristina Masini
No relevant relationships to disclose
Donatello Gasparro
No relevant relationships to disclose
Michele Milella
No relevant relationships to disclose
Alessandra Felici
No relevant relationships to disclose
Rossana Berardi
No relevant relationships to disclose
Saverio Cinieri
No relevant relationships to disclose
Nicola Calvani
No relevant relationships to disclose
Giovanni Lo Re
No relevant relationships to disclose
Giuseppe Banna
No relevant relationships to disclose
Helga Lipari
No relevant relationships to disclose
Maria Pia Brizzi
No relevant relationships to disclose
Sergio Bracarda
No relevant relationships to disclose
Michele Sisani
No relevant relationships to disclose
Camillo Porta
No relevant relationships to disclose
Enzo Galligioni
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Antonio Silverio Contu
No relevant relationships to disclose